Arrendar el dinero del rey. Fraude y estrategias financieras en el Estrado de las Rentas en la Castilla del siglo XV

This article explores the royal income from leasing of Castile in the second half of the fifteenth century, from the standpoint of the business tax. The complex administrative process involving the hiring of income can not be understood solely as a mechanism of tax collection, but must be related to other fields of economic and political action related to fiscal and financial business. This paper mainly emphasizes on analyzing some of the mechanisms developed in the auctions of the income that allowed business people to become landlords of certain tributes.El presente artículo profundiza en el arrendamiento de rentas regias de la Castilla de la segunda mitad del siglo XV, desde la óptica del negocio fiscal. El complejo proceso administrativo que suponen los arrendamientos de rentas no puede entenderse, únicamente, como un medio de percepción fiscal, sino que hay que conectarlo con otro tipo de campos de actuación política y económica relacionados con el negocio fiscal y financiero. Este trabajo analiza algunos de los mecanismos desarrollados en las subastas de las rentas, que permitían a los hombres de negocios convertirse en arrendadores de determinados tributos

Street walking quality of the ‘Centro’ district, Madrid

Walking provides a number of health, social and environmental benefits for urban sustainability, which is why it has become attractive from the perspective of sustainable transport planning. The concept of walkability is related with the built environment and land use to facilitate walking to activities in an area. The aim of this work is to provide a set of street walking quality maps for the ‘Centro’ district in Madrid (Spain), covering four categories of walking needs: attractiveness, comfort, safety and accessibility. They classify the streets from least to most walkable in relation to each other. The maps are built using 21 urban environmental factors selected from the literature. The values for each factor are computed in each street from open access databases and combined following the PROMETHEE II method function in order to assign a street value for each of the four classes of walking needs

El corrector de Planeta

Aquí se muestra parte de la tecnología que se está desarrollando en Planeta Actimedia, S.A., el centro tecnológico del grupo Planeta. Se trata del prototipo de un corrector orto tipográfico y gramatical que ha sido creado dentro del marco del proyecto SCASEM (Sistema de Catalogación Semántica), cuyo objetivo es la introducción de la tecnología del procesamiento del lenguaje natural dentro del entorno editorial del Grupo Planeta

A randomized placebo controlled clinical trial to evaluate the efficacy and safety of minocycline in patients with Angelman syndrome (A-MANECE study)

Background: Minocycline is an old tetracycline antibiotic that has shown antiinflammatory and antiapoptotic properties in different neurological disease mouse models. Previous single arm study in humans demonstrated benefits in individuals with Angelman Syndrome (AS); however, its efficacy in patients with Angelman Syndrome has not been assessed in a controlled trial. This was a randomized, double-blind, placebo-controlled, crossover trial in individuals with AS, aged 6 years to 30 years (n = 32, mean age 12 [SD 6·29] years). Participants were randomized to minocycline or placebo for 8 weeks and then switched to the other treatment (a subset of 22 patients) or to receive minocycline for up to 16 weeks (10 patients). After week 16, all patients entered a wash-out 8-week follow-up period. Results: Thirty-six subjects were screened and 34 were randomized. Thirty two subjects (94·1%) completed at least the first period and all of them completed the full trial. Intention-to-treat analysis demonstrated the lack of significantly greater improvements in the primary outcome, mean changes in age equivalent of the development index of the Merrill-Palmer Revised Scale after minocycline compared with placebo (1·90 ± 3·16 and 2·00 ± 3·28, respectively, p = 0·937). Longer treatment duration up to 16 weeks did not result in better treatment outcomes (1·86 ± 3·35 for 8 weeks treatment vs 1·20 ± 5·53 for 16 weeks treatment, p = 0·667). Side effects were not significantly different during minocycline and placebo treatments. No serious adverse events occurred on minocycline. Conclusions: Minocycline treatment for up to 16 weeks in children and young adults with AS resulted in lack of significant improvements in development indexes compared to placebo treatment. Treatment with minocycline appears safe and well tolerated; even if it cannot be completely ruled out that longer trials might be required for a potential minocycline effect to be expressed, available results and lack of knowledge on the actual mechanism of action do not support this hypothesis. Trial registration: European Clinical Trial database (EudraCT 2013-002154-67), registered 16th September 2013; US Clinical trials database (NCT02056665), registered 6th February 2014.Depto. de Psicología Experimental, Procesos Cognitivos y LogopediaFac. de PsicologíaTRUEpu

A randomized placebo controlled clinical trial to evaluate the efficacy and safety of minocycline in patients with Angelman syndrome (A-MANECE study)

Abstract Background Minocycline is an old tetracycline antibiotic that has shown antiinflammatory and antiapoptotic properties in different neurological disease mouse models. Previous single arm study in humans demonstrated benefits in individuals with Angelman Syndrome (AS); however, its efficacy in patients with Angelman Syndrome has not been assessed in a controlled trial. This was a randomized, double-blind, placebo-controlled, crossover trial in individuals with AS, aged 6 years to 30 years (n = 32, mean age 12 [SD 6·29] years). Participants were randomized to minocycline or placebo for 8 weeks and then switched to the other treatment (a subset of 22 patients) or to receive minocycline for up to 16 weeks (10 patients). After week 16, all patients entered a wash-out 8-week follow-up period. Results Thirty-six subjects were screened and 34 were randomized. Thirty two subjects (94·1%) completed at least the first period and all of them completed the full trial. Intention-to-treat analysis demonstrated the lack of significantly greater improvements in the primary outcome, mean changes in age equivalent of the development index of the Merrill-Palmer Revised Scale after minocycline compared with placebo (1·90 ± 3·16 and 2·00 ± 3·28, respectively, p = 0·937). Longer treatment duration up to 16 weeks did not result in better treatment outcomes (1·86 ± 3·35 for 8 weeks treatment vs 1·20 ± 5·53 for 16 weeks treatment, p = 0·667). Side effects were not significantly different during minocycline and placebo treatments. No serious adverse events occurred on minocycline. Conclusions Minocycline treatment for up to 16 weeks in children and young adults with AS resulted in lack of significant improvements in development indexes compared to placebo treatment. Treatment with minocycline appears safe and well tolerated; even if it cannot be completely ruled out that longer trials might be required for a potential minocycline effect to be expressed, available results and lack of knowledge on the actual mechanism of action do not support this hypothesis. Trial registration European Clinical Trial database (EudraCT 2013-002154-67), registered 16th September 2013; US Clinical trials database (NCT02056665), registered 6th February 2014